The observation that VEGF-D is associated with lymphatic disease rather than lung function decline or other aspects of disease activity or phenotype is consistent with a recent clinical trial where VEGF-D in patients with LAM was suppressed by inhibition of the mTOR pathway but did not parallel changes in lung function [15]. Here, VEGFD is linked to lymphatic system disorder.